They concluded that when compared to a therapeutic dose of heparin alone, using a P2Y12 inhibitor in addition to heparin did not improve the number of organ support-free days throughout the 21-day hospital stay for noncritically ill COVID‐19 patients [17]. The gene discussed is P2RY12; the disease is COVID-19.